Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.06 USD | -0.02% | +0.33% | -12.21% |
May. 20 | Exelixis Settles Cabometyx Patent Litigation with Cipla | MT |
May. 14 | Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.40% | 6.13B | B | ||
+8.65% | 115B | B+ | ||
+13.20% | 107B | B+ | ||
-13.71% | 22.31B | B+ | ||
-3.67% | 21.6B | B | ||
-5.96% | 18.23B | B | ||
-39.93% | 17.62B | A- | ||
+7.52% | 14.26B | C+ | ||
+33.85% | 12.37B | C+ | ||
-27.65% | 8.28B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EXEL Stock
- Ratings Exelixis, Inc.